by Maria Zannes | Jul 28, 2020 | Press Releases
JULY 28, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech company, today announced it has closed a non-brokered, secured convertible note (“Note”) financing for proceeds of $5,000,000.00 (the “Offering”). The proceeds...
by Maria Zannes | Jul 7, 2020 | Press Releases
OrbiMed Partner and Co-Founder of Alexion increases leadership role in oncology focused private company JULY 7, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held cancer diagnostics and therapeutics company, today announced that Stephen Squinto, Ph.D.,...
by Maria Zannes | Jun 16, 2020 | Press Releases
Philanthropist was Devoted to Bringing Life-Saving Tests and Treatments to Those In Need JUNE 16, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biomedical company, today named its research laboratories in memoriam of Harvey Sandler, a businessman...
by Maria Zannes | Jun 10, 2020 | Press Releases
Trial results of automated test demonstrate non-invasive CyPath® Lung is highly accurate in finding lung cancer FAQ: Answers to Questions about Cypath® Lung JUNE 10, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced its...
by Maria Zannes | Oct 11, 2019 | Events, Press Releases
OCTOBER 11, 2019 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech company, today announced that it has been accepted as a member of the American Cancer Society’s National Lung Cancer Roundtable (NLCRT), a collaborative whose membership is focused...
by Maria Zannes | Oct 2, 2019 | Press Releases
OCTOBER 2, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the members of its Scientific and Medical Advisory (SMA) Board who will provide independent expert advice and counsel on the Company’s research and...
